Seres Therapeutics (MCRB) Net Equity Issued and Repurchased (2015 - 2026)

Seres Therapeutics has reported Net Equity Issued and Repurchased for 8 years, with the latest figure at $400000.0 in Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 59.84% year-over-year to $400000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.6 million (down 52.43% YoY) and the FY2025 annual result came in at $13.2 million, down 44.04% from the prior year.
• Net Equity Issued and Repurchased fell to $400000.0 in Q1 2026 per MCRB's latest filing, from $12.2 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $22.0 million in Q4 2024 and troughed at -$11.7 million in Q4 2023.
• A 5-year average of $5.4 million and a median of $3.8 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2023 and 2024: Net Equity Issued and Repurchased sank 257.73% in 2023, then soared 334.38% in 2024.
• Over 5 years, Net Equity Issued and Repurchased stood at -$3.3 million in 2022, then tumbled by 257.73% to -$11.7 million in 2023, then surged by 287.95% to $22.0 million in 2024, then slumped by 44.79% to $12.2 million in 2025, then sank by 96.71% to $400000.0 in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $400000.0, $12.2 million, and $996000.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.